Quick Order Cart

Cat. No. ARG43764

C3 Knockout THP-1 Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Blood (peripheral blood)

  • Disease:

    Acute monoblastic leukemia

The C3 Knockout THP-1 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from human THP-1 monocytic cells, offering a defined loss-of-function model for complement component C3. This line abrogates expression of C3, a central opsonin and anaphylatoxin precursor, and is designed for studies of complement-dependent innate immunity, phagocytosis, and inflammatory signaling. C3 is regulated by NF-??B and IL-6 and mediates downstream signaling through C3aR and opsonin receptors CR1/CR3/CR4. The knockout model is appropriate for complement cascade analysis, host-pathogen interaction assays, drug screening, and autoimmune disease research. Typical readouts include C3a/C3b ELISA and phagocytosis of opsonized targets.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    THP-1

    Sex of Donor

    Male

    Age

    1 year

    Derived From Site

    In situ; Peripheral blood

    Gene Name

    C3

    Gene Identifier

    NCBI Gene ID 718

    Growth Mode

    Suspension

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% COâ‚‚

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The C3 Knockout THP-1 Cell Line is a CRISPR/Cas9-edited knockout cell line engineered to disrupt the C3 gene in human THP-1 monocytic cells. This loss-of-function model eliminates complement component C3, a central mediator of complement-driven opsonization, anaphylatoxin signaling, and innate immune regulation.

THP-1 cells are an acute monocytic leukemia-derived monocyte-like line from a one-year-old male. Widely used for their ability to differentiate into macrophage-like cells, they retain phagocytic activity and responsiveness to inflammatory stimuli, making them a standard model for innate immunity, host-pathogen interactions, and cancer biology studies.

C3 encodes complement C3, a pivotal protein of the complement system. It is activated by the classical, lectin, and alternative pathways, generating C3a (anaphylatoxin) and C3b (opsonin). C3a signals through C3aR to drive inflammation, while C3b tags pathogens for phagocytosis via CR1 (CD35), CR3, and CR4. C3 expression is regulated by IL-1??, IL-6, TNF-??, NF-??B, STAT3, LPS, IFN-??, and C/EBP??. In the cascade, C3b forms part of the C3 convertases (C4b2a, C3bBb) with Factor B, Factor D, and Properdin, and is controlled by Factor H and Factor I. C3b also contributes to C5 convertase generation. Thus, C3 knockout abrogates opsonin-mediated phagocytosis and C3a/C3aR signaling.

In THP-1 monocytes, the loss of C3 disrupts complement-dependent phagocytosis and alters differentiation-related responses. This knockout model is ideal for dissecting C3-dependent innate immune functions, particularly how C3 fragments influence monocyte inflammatory signaling through NF-??B and STAT3 pathways under LPS or cytokine stimulation. It is relevant to studying complement dysregulation in atypical hemolytic uremic syndrome, C3 glomerulopathy, and systemic lupus erythematosus.

Applications include complement system studies in monocytic cells, host-pathogen interaction assays requiring opsonization, and screening of complement-targeted therapeutics. Representative assays: Western blot for C3, RT-qPCR, C3a/C3b ELISA, phagocytosis of opsonized targets, flow cytometry of complement receptors, and macrophage differentiation with complement stimulation. These tools support research in inflammation, autoimmunity, and innate immunity. For further information, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)